Skip to main content
. 2010 Feb;77(2):159–170. doi: 10.1124/mol.109.060673

Fig. 1.

Fig. 1.

Chemical structures of the most potent FPR1/FPR2 agonists selected by high-throughput screening. Chemical names for these compounds are: AG-09/1, 2-(6-methoxybenzimidazol-2-ylthio)-N-(4-nitrophenyl)acetamide; AG-09/2, N-(4-ethoxyphenyl)-2-(6-methoxybenzimidazol-2-ylthio)acetamide; AG-26, N-(4-chlorophenyl)-N′-[2-(4-methoxyphenyl)ethyl]urea; AG-09/3, N-(4-bromophenyl)-2-[4-(4-fluorophenyl)piperazinyl]acetamide; AG-09/4, N-(4-bromophenyl)-2-[4-(3-chlorophenyl)piperazinyl]acetamide; AG-09/5, N′-(4-chlorobenzoyl)-2-nitrobenzohydrazide; AG-09/6, N-(4-methoxyphenyl)-5-(2-thienyl)pentanamide; AG-09/7, N′-[2-nitro-(Z)-styrylmethylene]-2-oxo-4-phenylpyrrolidine-3-carbohydrazide; AG-09/8, N-[2-(4-methoxyphenyl)-4-oxo-1,2,3-trihydroquinazolin-3-yl]-4-nitrobenzamide; AG-09/9, N-[2-(indol-3-yl)-1,3-thiazolidin-4-one-3-yl]-N′-(4-methoxyphenyl)thiourea; AG-09/10, N-(4-methoxyphenyl)-N′-[4-(1-piperidinylcarbonyl)phenyl]urea; AG-22, N′-[(3-thienyl)methylene]-2-[4-(2-pentyl)phenoxy]acetylhydrazide.